9,128 results match your criteria intravitreal administration

Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 2. THR-687.

J Pharmacokinet Pharmacodyn 2021 Jul 23. Epub 2021 Jul 23.

Oxurion N.V, Gaston Geenslaan 1, 3001, leuven, Belgium.

Intravitreal (IVT) injection remains the preferred administration route of pharmacological agents intended for the treatment of back of the eye diseases such as diabetic macular edema (DME) and neovascular age-related macular degeneration (nvAMD). The procedure enables drugs to be delivered locally at high concentrations whilst limiting whole body exposure and associated risk of systemic adverse events. Nevertheless, intravitreally-delivered drugs do enter the general circulation and achieving an accurate understanding of systemic exposure is pivotal for the evaluation and development of drugs administered in the eye. Read More

View Article and Full-Text PDF

Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 1. THR-149.

J Pharmacokinet Pharmacodyn 2021 Jul 23. Epub 2021 Jul 23.

Oxurion N.V., Gaston Geenslaan 1, 3001, Leuven, Belgium.

Intravitreal (IVT) injection of pharmacological agents is an established and widely used procedure for the treatment of many posterior segment of the eye diseases. IVT injections permit drugs to reach high concentrations in the retina whilst limiting systemic exposure. Beyond the risk of secondary complications such as intraocular infection, the potential of systemic adverse events cannot be neglected. Read More

View Article and Full-Text PDF

Implementation of Teleretinal Screening Using Optical Coherence Tomography in the Veterans Health Administration.

Telemed J E Health 2021 Jul 12. Epub 2021 Jul 12.

Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.

pp Read More

View Article and Full-Text PDF

CD146/Soluble CD146 Pathway Is a Novel Biomarker of Angiogenesis and Inflammation in Proliferative Diabetic Retinopathy.

Invest Ophthalmol Vis Sci 2021 Jul;62(9):32

University Hospitals, UZ Gasthuisberg, Leuven, Belgium.

Purpose: Inflammation, angiogenesis and fibrosis are pathological hallmarks of proliferative diabetic retinopathy (PDR). The CD146/sCD146 pathway displays proinflammatory and proangiogenic properties. We investigated the role of this pathway in the pathophysiology of PDR. Read More

View Article and Full-Text PDF

Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study).

Eur J Ophthalmol 2021 Jul 20:11206721211033480. Epub 2021 Jul 20.

Allergan, an AbbVie company, Courbevoie, France.

Purpose: INVICOST, a medico-economic analysis, compared costs of managing treatment-naive patients with diabetic macular edema (DME) receiving intravitreal injections (IVIs) of aflibercept (AFL), dexamethasone implant (DXI) or ranibizumab (RAN) over 1 year.

Methods: Healthcare resource use and associated costs were estimated using individual patient data from INVICTUS, a prospective, open-label, monocentric study. Healthcare costs comprised direct medical costs such as drug acquisition and administration, consultations and ophthalmological procedures. Read More

View Article and Full-Text PDF

Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis.

Syst Rev 2021 Jul 19;10(1):206. Epub 2021 Jul 19.

NeURos Research Group, Escuela de Medicina Y Ciencias de La Salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia.

Background: Ocular toxoplasmosis (OT) is the most common cause of posterior uveitis, which leads to visual impairment in a large proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual loss by controlling infection and inflammation. However, there remains disagreement regarding optimal antibiotic therapy for OT. Read More

View Article and Full-Text PDF

Intravitreal brimonidine inhibits form-deprivation myopia in guinea pigs.

Eye Vis (Lond) 2021 Jul 14;8(1):27. Epub 2021 Jul 14.

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China.

Background: The use of ocular hypotensive drugs has been reported to attenuate myopia progression. This study explores whether brimonidine can slow myopia progression in the guinea pig form-deprivation (FD) model.

Methods: Three-week-old pigmented male guinea pigs (Cavia porcellus) underwent monocular FD and were treated with 3 different methods of brimonidine administration (eye drops, subconjunctival or intravitreal injections). Read More

View Article and Full-Text PDF

Multiple Intravitreal Liposomal Amphotericin B for a Case of Endophthalmitis.

Case Rep Ophthalmol 2021 May-Aug;12(2):485-491. Epub 2021 Jun 11.

Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.

We report a case of endophthalmitis which was effectively treated by intravitreal liposomal amphotericin B (L-AMB) injection. A 72-year-old man was referred to our department for positive blood culture of . First ophthalmologic examination revealed a chorioretinal lesion in left eye, and the patient was diagnosed as possible candida chorioretinitis. Read More

View Article and Full-Text PDF

Does ganciclovir exert retinal toxicity after multiple continuous intravitreal injections?

BMC Infect Dis 2021 Jul 12;21(1):676. Epub 2021 Jul 12.

Beijing Institute of Ophthalmology, 17 Hougou Lane, Chongnei Street, Beijing, 100005, People's Republic of China.

Background: The objective of this study is to report a case of acute retinal necrosis in which abnormalities in visual function did not correspond to retinal anatomical outcomes.

Case Presentation: A 39-year-old female diagnosed with acute retinal necrosis underwent repeated (nine rounds) intravitreal ganciclovir injection (3 mg/0.1 ml) into the left eye, one injection every 2 weeks. Read More

View Article and Full-Text PDF

Intraocular Foreign Bodies: Clinical Characteristics and Factors Affecting Visual Outcome.

J Ophthalmol 2021 18;2021:9933403. Epub 2021 Jun 18.

Department of Ophthalmology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.

Objective: To investigate the clinical characteristics and factors affecting visual outcome in patients with intraocular foreign bodies (IOFBs) and determine the risk factors for the development of endophthalmitis. . A retrospective case-series study design was adopted. Read More

View Article and Full-Text PDF

Hyaluronic-Coated Albumin Nanoparticles for the Non-Invasive Delivery of Apatinib in Diabetic Retinopathy.

Int J Nanomedicine 2021 2;16:4481-4494. Epub 2021 Jul 2.

Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.

Purpose: Apatinib (Apa) is a novel anti-vascular endothelial growth factor with the potential to treat diabetic retinopathy (DR); a serious condition leading to visual impairment and blindness. DR treatment relies on invasive techniques associated with various complications. Investigating topical routes for Apa delivery to the posterior eye segment is thus promising but also challenging due to ocular barriers. Read More

View Article and Full-Text PDF

Inhibition of mTOR signaling by rapamycin protects photoreceptors from degeneration in mice.

Zool Res 2021 Jul;42(4):482-486

Key Laboratory for Human Disease Gene Study of Sichuan Province and Institute of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.

Retinitis pigmentosa (RP) is an inherited retinal degenerative disease that begins with defective rod photoreceptor function, followed by impaired cone function, and complete blindness in its late stage. To date, however, there is no effective treatment for RP. By carrying a nonsense mutation in the gene, mice display elevated cGMP in conjunction with higher intracellular Ca in their rod photoreceptors, resulting in fast retinal degeneration. Read More

View Article and Full-Text PDF

The effect of topical ocular moxifloxacin on conjunctival and nasal mucosal flora.

Sci Rep 2021 Jul 2;11(1):13782. Epub 2021 Jul 2.

Department of Otorhinolaryngology, Eregli State Hospital, Toros Mah. Yurt Cad. No: 13, Eregli, 42000, Konya, Turkey.

To determine the short-term effect of topically administered ocular moxifloxacin on conjunctival and nasal bacterial mucosal flora. The study included 20 patients with newly diagnosed age-related macular degeneration. Each patient's diseased eye was selected as the treatment eye and the fellow eye was selected as the control eye. Read More

View Article and Full-Text PDF

Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization.

Clin Ophthalmol 2021 25;15:2753-2758. Epub 2021 Jun 25.

Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

Aim: Evaluation of real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in the primary treatment of choroidal neovascularization (CNV) secondary to pathological myopia.

Patients And Methods: A retrospective cohort analysis of treatment naive patients with myopic CNV who received treatment with either intravitreal ranibizumab or aflibercept over a 12-year period from September 2007 to May 2020 was performed. Baseline features, treatment factors and outcomes were compared between younger and older patients and final visual outcome was assessed for associated factors. Read More

View Article and Full-Text PDF


J Pharmacol Exp Ther 2021 Jul 1. Epub 2021 Jul 1.

AbbVie Inc., United States.

Brimonidine, a selective alpha-adrenoceptor agonist, displays putative retinal cyto-neuroprotective activity and An intravitreal sustained-release brimonidine implant, Brimonidine Posterior Segment Drug Delivery System (brimonidine DDS), allowing targeted drug delivery to the retina, has been developed for potential clinical application. This study evaluates the posterior segment pharmacokinetics of brimonidine DDS implant in the monkey eye, and applies translational pharmacokinetic modeling to predict tissue exposure in the human eye. Anesthetized Cynomolgus monkeys received a single intravitreal injection of brimonidine DDS 400 µg implant before removal of study eyes at Days 7, 30, 60, 92, 120, and 150 post-implant (3-4 animals per time point) for assay of brimonidine in aqueous humor, vitreous, and retina samples. Read More

View Article and Full-Text PDF

Neuroprotective Effect of siRNA Entrapped in Hyaluronic Acid-Coated Lipoplexes by Intravitreal Administration.

Pharmaceutics 2021 Jun 8;13(6). Epub 2021 Jun 8.

Faculdade de Farmácia, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Brazil.

Since the possibility of silencing specific genes linked to retinal degeneration has become a reality with the use of small interfering RNAs (siRNAs), this technology has been widely studied to promote the treatment of several ocular diseases. Despite recent advances, the clinical success of gene silencing in the retina is significantly reduced by inherent anatomical and physiological ocular barriers, and new strategies are required to achieve intraocular therapeutic effectiveness. In this study, we developed lipoplexes, prepared with sodium alginate as an adjuvant and strategically coated with hyaluronic acid (HA-LIP), and investigated the potential neuroprotective effect of these systems in a retinal light damage model. Read More

View Article and Full-Text PDF

Determination of the retinal toxicity of intravitreal colistin in rabbit eyes.

Cutan Ocul Toxicol 2021 Jun 30:1-5. Epub 2021 Jun 30.

Department of Ophthalmology, Medipol University Medical School, Istanbul, Turkey.

Purpose: To determine the possible adverse effects and safe dose range of intravitreal colistin, an antibiotic, after its intravitreal application.

Methods: Twenty eyes of 20 adult male and female New Zealand white rabbits were selected. Various concentrations of colistin were prepared. Read More

View Article and Full-Text PDF

Mechanistic Model for the Prediction of Small-Molecule Vitreal Clearance Combining Diffusion-Limited and Permeability-Limited Clearance.

Mol Pharm 2021 Jul 21;18(7):2703-2713. Epub 2021 Jun 21.

Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.

The discovery of new small-molecule drugs for intravitreal administration would benefit from simple models to predict vitreal clearance (CL). The current models available have limitations in their applicability to small-molecule drugs and translatability to humans. We developed a mechanistic model combining the diffusion rate of the molecule in the vitreous and permeability across posterior segment tissues and applied it to 30 small molecules with observed CL available mostly from literature. Read More

View Article and Full-Text PDF

Reworking protocols of ophthalmic resident surgical training in the COVID-19 era - Experiences of a tertiary care institute in northern India.

Indian J Ophthalmol 2021 Jul;69(7):1928-1932

Department of Ophthalmology, Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Purpose: Coronavirus Disease 2019 (COVID-19) pandemic has negatively impacted medical professionals in all fields of medicine and surgery in their academic, clinical and surgical training. The impact of surgical training has been described as 'severe' by most ophthalmology residents worldwide due to their duties in COVID-19 wards, disruption of outpatient and camp services.

Methods: Ophthalmic surgery demands utmost accuracy and meticulousness. Read More

View Article and Full-Text PDF

Short-Term Efficacy Of Intravitreal Bevacizumab In Treatment Naive Patients- Real World Evidence In Pakistan.

J Ayub Med Coll Abbottabad 2021 Apr-Jun;33(2):183-187

Medical Retina Clinic, Amanat Eye Hospital, Rawalpindi, Pakistan.

Background: Anti-VEGF agents have been proven to be effective in treating macular oedema secondary to a multitude of pathological conditions. However, in large clinical trial settings, the results may be overstated. This study aimed to evaluate the short-term efficacy of intraocular Bevacizumab in consecutive patients with macular oedema being treated in a 'real-world' setting in Pakistan. Read More

View Article and Full-Text PDF

Comparison of Two Different Intravitreal Injection Techniques.

Clin Ophthalmol 2021 8;15:2383-2389. Epub 2021 Jun 8.

St. Luke's Medical Center Global City, Taguig City, Philippines.

Objective: To compare the effectiveness, procedure time and safety outcomes of two different intravitreal injections (IVI) techniques.

Methods: This was a prospective, single-center, randomized clinical trial of 200 adult eyes receiving intravitreal medications for various indications. Eyes were assigned (1:1) to undergo IVI using either an intravitreal injection guide (IIG) (n= 100) or conventional dual blade speculum plus surgical caliper (DBS) (n=100). Read More

View Article and Full-Text PDF

Cynaroside protects the blue light-induced retinal degeneration through alleviating apoptosis and inducing autophagy in vitro and in vivo.

Phytomedicine 2021 Jul 24;88:153604. Epub 2021 May 24.

State Key Laboratory of Natural Medicines, Department of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. Electronic address:

Background: Blue light can directly penetrate the lens and reach the retina to induce retinal damage, causing dry age-related macular degeneration (dAMD). Cynaroside (Cyn), a flavonoid glycoside, was proved to alleviate the oxidative damage of retinal cells in vitro. However, whether or not Cyn also exerts protective effect on blue light-induced retinal degeneration and its mechanisms of action are unclear. Read More

View Article and Full-Text PDF

Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib Suspension Via Ocular and Systemic Disposition in Rabbits.

Transl Vis Sci Technol 2021 06;10(7):19

Clearside Biomedical Inc., Alpharetta, GA, USA.

Purpose: Axitinib, a tyrosine kinase inhibitor, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptors -1, -2 and -3. Suprachoroidal (SC) delivery of axitinib, combined with pan-VEGF inhibition activity of axitinib, has the potential to provide additional benefits compared to the current standard of care with intravitreal anti-VEGF-A agents. This study evaluated the ocular pharmacokinetics and systemic disposition of axitinib after SC administration in rabbits. Read More

View Article and Full-Text PDF

Chitosan coated nanoparticles for efficient delivery of bevacizumab in the posterior ocular tissues via subconjunctival administration.

Carbohydr Polym 2021 Sep 18;267:118217. Epub 2021 May 18.

Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard, Hamdard Nagar, New Delhi, India.

In several ocular diseases, vascular endothelial growth factor (VEGF) level has been found to be unregulated. Bevacizumab, an anti-VEGF drug, is the most commonly used off level drug for diabetic retinopathy (DR). The present study was to evaluate the chitosan-coated poly (lactide-co-glycolic acid) nanoparticles (CS-PLGA NPs) for sustained and effective delivery of bevacizumab to posterior ocular tissues. Read More

View Article and Full-Text PDF
September 2021

Laser-induced choroidal neovascularization: A case report and some reflection on animal models for age-related macular degeneration.

Medicine (Baltimore) 2021 Jun;100(23):e26239

Department of Ophthalmology, the First Affiliated Hospital of Soochow University.

Rationale: Laser induced maculopathy includes retinal photoreceptor disruption, macular hole, macular hemorrhage, and rarely choroidal neovascularization (CNV). Here we report a case of laser induced CNV that was treated by intravitreal anti-vascular endothelial growth factor (VEGF) injection and resulted in visual improvement and CNV resolution during 1-year follow up. In addition, the case of laser induced CNV treated with intravitreal anti-VEGF injections are reviewed for the first time in literature. Read More

View Article and Full-Text PDF

Prophylactic effect of brinzolamide-brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections.

Int Ophthalmol 2021 Jun 10. Epub 2021 Jun 10.

Department of Ophthalmology, "Elpis" General Hospital of Athens, 7 Dimitsanas Street, 115 22, Athens, Greece.

Purpose: To evaluate the effect of topical prophylaxis with brinzolamide-brimonidine fixed combination on short-term intraocular pressure (IOP) elevation after intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF).

Methods: This prospective comparative study included 56 eyes of 47 patients treated with intravitreal injections of anti-VEGF, and they were randomly divided into two groups. In control group (25 eyes), no prophylactic medication was used, whereas in case group (31 eyes) one drop of a fixed combination of brinzolamide-brimonidine was instilled two hours before the injection. Read More

View Article and Full-Text PDF

Simultaneous quantification of dexamethasone and 6β-hydroxydexamethasone in rabbit plasma, aqueous and vitreous humor, and retina by UHPLC-MS/MS.

Bioanalysis 2021 Jul 8;13(13):1051-1062. Epub 2021 Jun 8.

Division of Product Quality Research, Office of Testing & Research, Office of Pharmaceutical Quality, US Food & Drug Administration, 10903 New Hampshire Ave., Life Sciences Building 64, Silver Spring, MD 20993, USA.

To develop and validate a fit for purpose method for the simultaneous determination of dexamethasone and its major metabolite, 6β-hydroxydexamethasone, in rabbit plasma and ocular matrices to measure the release and distribution profile of dexamethasone from intravitreal implants. An UHPLC-MS/MS system was employed to perform the bioanalysis. The method was validated according to the US FDA Bioanalytical Method Validation Guidance for Industry. Read More

View Article and Full-Text PDF

Management of cataracts secondary to intravitreal chemotherapy injections for retinoblastoma seeding.

Eur J Ophthalmol 2021 Jun 3:11206721211023317. Epub 2021 Jun 3.

Ocular Oncology Service, Department of Ophthalmology, Hacettepe University School of Medicine, Ankara, Turkey.

Purpose: To report our experience in the management of cataracts presumably due to intravitreal chemotherapy administration in eyes with vitreous disease associated with retinoblastoma.

Methods: This retrospective study consisted of a cohort of five eyes of five retinoblastoma patients who developed cataracts secondary to intravitreal chemotherapy administration and who then underwent cataract surgery. All patients underwent lensectomy and anterior vitrectomy with/without intraocular lens implantation via clear corneal approach. Read More

View Article and Full-Text PDF